In vitro immune monitoring of antibody response in dogs given chemoimmunotherapy for lymphoma.
Clinical remission in 30 dogs with lymphoma was induced with a combination of vincristine, L-asparaginase, cyclophosphamide, and doxorubicin HCl, administered sequentially, and then an autochthonous tumor cell vaccine, given intralymphatically, as maintenance therapy. Humoral antibody amounts were monitored in 11 dogs, using a solid-phase bead-type radioimmunoassay. The median survival of the 30 dogs was 13 months from the start of chemotherapy (range, 7 to 25 months; mean, 13.8). The median remission duration was 16 weeks (range, 9 to 98 weeks; mean, 26.8). Correlation between increase in amount of humoral antibody was significant (P = 0.0001 to 0.012), before and after chemoimmunotherapy, in dogs responding to therapy, compared with that in dogs not responding to therapy.
Jeglum
K A
KA
Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia 19104-6010.
Winters
W D
WD
Young
K M
KM
D000818:Animals; D000912:Antibodies, Neoplasm / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004283:Dog Diseases / Q000188:drug therapy / Q000276:immunology* / Q000628:therapy; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D007167:Immunotherapy / Q000662:veterinary*; D008223:Lymphoma / Q000188:drug therapy / Q000276:immunology / Q000628:therapy / Q000662:veterinary*; D008297:Male; D013997:Time Factors; D014612:Vaccines / Q000008:administration & dosage / Q000276:immunology; D014750:Vincristine / Q000008:administration & dosage
D000912:Antibodies, Neoplasm; D014612:Vaccines; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D001215:Asparaginase